NCT04634669 - Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) | Biotech Hunter

Enrollment

186

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions

Treatment Resistant DepressionMajor Depressive Disorder

Interventions

DRUG

AXS-05 (dextromethorphan-bupropion)

\- AXS-05 tablet, taken daily (up to 15 months)

Trial Locations (20)

10312

Clinical Research Site, Staten Island

14618

Clinical Research Site, Rochester

19063

Clinical Research Site, Media

27609

Clinical Research Site, Raleigh

28601

Clinical Research Site, Hickory

32081

Clinical Research Site, Orlando

33122

Clinical Research Site, Miami

33161

Clinical Research Site, North Miami

44130

Clinical Research Site, Middleburg Heights

45215

Clinical Research Site, Cincinnati

60634

Clinical Research Site, Chicago

72209

Clinical Research Site, Little Rock

75243

Clinical Research Site, Dallas

77546

Clinical Research Site, Friendswood

91403

Clinical Research Site, Sherman Oaks

91786

Clinical Research Site, Upland

92374

Clinical Research Site, Redlands

98201

Clinical Research Site, Everett

02131

Clinical Research Site, Boston

08009

Clinical Research Site, Berlin